Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL28258996 | 0.87 | CNR2 (0.54) | CNR2RORCMAPTTSHRPIN1 | |
| SCHEMBL4115523 | 0.87 | CNR2 (0.53) | CNR2RORCTSHRCYP3A4 | |
| SCHEMBL9211 | 0.85 | ALDH1A1 (0.49) | CNR2RORCMAPTTSHRABCB11 | |
| SCHEMBL8173029 | 0.85 | CNR2 (0.48) | CNR2RORCTSHRABCB11CYP1A2 | |
| SCHEMBL6677336 | 0.85 | ABCB11 (0.61) | CNR2RORCTSHRABCB11CYP1A2 | |
| SCHEMBL397134 | 0.85 | CYP1A2 (0.53) | CNR2RORCMAPTNPC1RAB9A | |
| SCHEMBL8434856 | 0.85 | RORC (0.53) | CNR2RORCMAPTTSHRABCB11 | |
| SCHEMBL1626657 | 0.85 | CNR2 (0.48) | CNR2RORCMAPTTSHRABCB11 | |
| SCHEMBL395978 | 0.85 | PIN1 (0.54) | CNR2RORCMAPTTSHRPIN1 | |
| Benzene SCHEMBL28258998 | 0.85 | PIN1 (0.54) | CNR2RORCMAPTTSHRPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
| US-7906644-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-6852863-B2 | Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1470109-A1 | METABOLITES OF (3- [(4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL -PHENOXY)-ACETIC ACID | Pfizer Products Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | CAMERON KIMBERLY O (US) | 2003-11-20 | — | — | US | disclosed |
| WO-2003064391-A1 | METABOLITES OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-0956286-B1 | SYNTHESIS OF TERFENADINE AND DERIVATIVES | SEPRACOR INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6147217-A | Synthesis of terfenadine and derivatives | SEPRACOR INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0956286-A1 | SYNTHESIS OF TERFENADINE AND DERIVATIVES | SEPRACOR, INC. (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5925761-A | Synthesis of terfenadine and derivatives | SEPRACOR INC. (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1998033789-A1 | SYNTHESIS OF TERFENADINE AND DERIVATIVES | SEPRACOR, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | CNR2 188/4885RORC 1341/4885MAPT 4104/4885 |
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | ABAT, BCAT2, PC | CNR2 1835/4885RORC 1949/4885MAPT 1487/4885 |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | GCK, GCKR, ALDOA | CNR2 3243/4885RORC 3822/4885MAPT 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.